- EPS Growth of 11% to 14% Projected
- Expanded PARTNER Trial to Include Transapical System
- European Approval Received for Transapical System
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Edwards Lifesciences Corporation (NYSE: EW), a world leader in products and technologies to treat advanced cardiovascular disease, today will provide investors with information on the initiatives expected to drive sales growth and profitability in 2008 and beyond. During its 2007 investor conference in New York City, Edwards' management will present details of the company's growth plans, market expansion opportunities and its financial outlook for 2008.
"We expect 2008 to be a very successful and important year for Edwards Lifesciences," said Michael A. Mussallem, chairman and CEO. "Our market-leading heart valve and critical care franchises provide a strong foundation for continued growth. We expect our strategic portfolio changes and sales of new products to drive greater profitability and grow earnings. Additionally, our market-expanding transcatheter valve technologies are expected to generate more than $20 million of sales next year."
During the conference, Edwards' management also will present the
company's financial goals for 2008, including total sales between $1.16
billion to $1.21 billion, increasing gross profit margin by 100 to 150
basis points, delivering earnings per share growth of 11 to 14 percent,
excluding the impact of special items, and generating free cash flow of
$155 million to $165 million.
Among the specific topics to be discussed at today's event are:
-- Transcatheter Heart Valve Therapy -- Edwards continues to lead the
|SOURCE Edwards Lifesciences Corporation|
Copyright©2007 PR Newswire.
All rights reserved